UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Vaccines and biologics

Annals of the Rheumatic Diseases, 2014-08, Vol.73 (8), p.1446-1454

2014

Volltextzugriff (PDF)

Evolution of biological agents: how established drugs can become less safe

BMJ (Online), 2017-04, Vol.357, p.j1707

2017

Volltextzugriff (PDF)

Neighbourhood characteristics and cumulative biological risk: evidence from the Jamaica Health and Lifestyle Survey 2008: a cross-sectional study

BMJ open, 2018-12, Vol.8 (12), p.e021952

2018

Volltextzugriff (PDF)

Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil

BMJ open, 2014-01, Vol.4 (3), p.e004179

2014

Volltextzugriff (PDF)

Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida

Archives of disease in childhood. Fetal and neonatal edition, 2003-09, Vol.88 (5), p.F446-446

2003

Volltextzugriff (PDF)

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Annals of the rheumatic diseases, 2016-10, Vol.75 (10), p.1843-1847

2016

Volltextzugriff (PDF)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Annals of the rheumatic diseases, 2022-03, Vol.81 (3), p.335-343

2022

Volltextzugriff (PDF)

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

Annals of the rheumatic diseases, 2019-04, Vol.78 (4), p.456-464

2019

Volltextzugriff (PDF)

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Annals of the rheumatic diseases, 2017-06, Vol.76 (6), p.1101-1136

2017

Volltextzugriff (PDF)

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis

Annals of the rheumatic diseases, 2020-02, Vol.79 (2), p.285-291

2020

Volltextzugriff (PDF)

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)

Annals of the rheumatic diseases, 2016-05, Vol.75 (5), p.855-861

2016

Volltextzugriff (PDF)

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

Annals of the rheumatic diseases, 2011-04, Vol.70 (4), p.616-623

2011

Volltextzugriff (PDF)

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study

Annals of the rheumatic diseases, 2014-11, Vol.73 (11), p.1942-1948

2014

Volltextzugriff (PDF)

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

BMJ (Online), 2019-01, Vol.364, p.l67

2019

Volltextzugriff (PDF)

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

Annals of the rheumatic diseases, 2018-02, Vol.77 (2), p.175-187

2018

Volltextzugriff (PDF)

Mycobacterial diseases and antitumour necrosis factor therapy in USA

Annals of the rheumatic diseases, 2013-01, Vol.72 (1), p.37-42

2013

Volltextzugriff (PDF)

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

Annals of the rheumatic diseases, 2013-02, Vol.72 (2), p.229-234

2013

Volltextzugriff (PDF)

Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

Gut, 2009-04, Vol.58 (4), p.492-500

2009

Volltextzugriff (PDF)

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

Annals of the rheumatic diseases, 2010-03, Vol.69 (3), p.522-528

2010

Volltextzugriff (PDF)

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Annals of the rheumatic diseases, 2011-11, Vol.70 (11), p.1914-1920

2011

Volltextzugriff (PDF)

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2023-01, Vol.82 (1), p.107-118

2023

Volltextzugriff (PDF)

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Annals of the rheumatic diseases, 2014-09, Vol.73 (9), p.1607-1615

2014

Volltextzugriff (PDF)

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

Annals of the Rheumatic Diseases, 2012-03, Vol.71 (3), p.319-326

2012

Volltextzugriff (PDF)

1 – 25 von 3.328

Suche als RSS-Feed

Aktive Filter

KollektionBMJ Journals

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(3.320)
Mit Volltextzugriff
(2.951)

Publikationsform

Artikel
(3.328)

Sprache

Englisch
(3.328)

Erscheinungsjahr

n.n

Thema

Humans
(3.274)
Biological And Medical Sciences
(3.159)
Life Sciences & Biomedicine
(3.135)
Science & Technology
(3.135)
Medical Sciences
(3.098)
Male
(2.327)
Female
(2.116)
Risk Factors
(1.861)
Middle Aged
(1.708)
Adult
(1.626)
Aged
(1.186)
Public, Environmental & Occupational Health
(1.166)
Time Factors
(747)
Studies
(721)
Mortality
(698)
Toxicology
(591)
Occupational Exposure - Adverse Effects
(566)
Adolescent
(550)
Epidemiology
(458)
Smoking - Adverse Effects
(439)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

MEDLINE
(3.327)
EZB Free E-Journals
(3.292)
Journals@Ovid Complete
(3.266)
BMJ Journals Archiv - DFG Nationallizenzen
(2.946)
JSTOR
(1.517)
Publisher or Other Site
(624)
Applied Social Sciences Index & Abstracts (ASSIA)
(206)
Oxford Journals
(76)
Wiley Online Library Journals
(6)
Springer Journals
(6)
Ingenta
(3)
SAGE Journals
(1)

7 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Occupational And Environmental Medicine
(985)
Annals Of The Rheumatic Diseases
(381)
Bmj
(290)
Bmj. British Medical Journal
(284)
British Journal Of Industrial Medicine
(256)
Journal Of Epidemiology And Community Health
(238)
Bmj : British Medical Journal
(232)
Archives Of Disease In Childhood
(229)
Thorax
(216)
Gut
(214)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Vaccines and biologics

Evolution of biological agents: how established drugs can become less safe

Neighbourhood characteristics and cumulative biological risk: evidence from the Jamaica Health and Lifestyle Survey 2008: a cross-sectional study

Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil

Methaemoglobinaemia with concurrent blood isolation of Saccharomyces and Candida

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study

B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis

Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis

Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA)

Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry

Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) Study

Comparative effectiveness of rituximab, abatacept, and tocilizumab in adults with rheumatoid arthritis and inadequate response to TNF inhibitors: prospective cohort study

Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn’s disease and ulcerative colitis?

Mycobacterial diseases and antitumour necrosis factor therapy in USA

Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register

Long-term outcome of treatment with infliximab in 614 patients with Crohn’s disease: results from a single-centre cohort

Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study

Early initiation of prophylactic anticoagulation for prevention of coronavirus disease 2019 mortality in patients admitted to hospital in the United States: cohort study

A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis

Aktive Filter

Suchergebnisse filtern